Pathophysiology of chronic heart failure

American Journal of Medicine

Volumn 110, Issue 7, 2001, Pages 37-46

  Francis, Gary S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; FLOSEQUINAN; PROSTACYCLIN; RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VASODILATOR AGENT;

CARDIOMYOPATHY; CLINICAL TRIAL; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; ENERGY METABOLISM; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART MUSCLE METABOLISM; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SODIUM RETENTION; WATER RETENTION;

EID: 0035821279     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(98)00385-4     Document Type: Review

References (94)

1. Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure
2. The development of positive inotropic agents for chronic heart failure: How have we gone astray?
3. How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease
4. Neurohumoral activation in preclinical heart failure: Remodeling and the potential for intervention
5. Left ventricular hypertrophy: An initial response to myocardial injury
6. Asymptomatic left ventricular dysfunction
7. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction
8. Epidemiology of congestive heart failure
9. Epidemiology of heart failure
10. Chronic heart failure in the United States: A manifestation of coronary artery disease
11. Cytoskeletal role in the transition from compensated to decompensated hypertrophy during adult canine left ventricular pressure overloading
12. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population
13. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
14. Ventricular remodeling after myocardial infarction: Experimental observations and clinical implications
15. Heart failure: Mechanisms of cardiac and vascular dysfunction and the rationale for pharmacologic intervention
16. Structural basis of end-stage failure in ischemic cardiomyopathy in humans
17. Progressive left ventricular dysfunction and remodeling after myocardial infarction: Potential mechanisms and early predictors
18. Post-infarction myocardial remodelling: Why does it happen?
19. Structural basis for heart failure: Ventricular remodeling and its pharmacological inhibition
20. Hypothetical pathways of cardiac myocyte hypertrophy: Response to myocardial injury
21. Apoptosis in the failing human heart
22. Myocyte cell death and ventricular remodeling
23. Apoptosis in myocytes in end-stage heart failure
24. The matrix-degrading metalloproteinases
25. Matrix metalloproteinase and cardiovascular disease
26. Extracellular matrix remodeling in heart failure: A role for de novo angiotensin II generation
27. Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy
28. The cellular basis of dilated cardiomyopathy in humans
29. Patterns of myocardial fibrosis
30. Fibrillar collagen and remodeling of dilated canine left ventricle
31. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system
32. Myocardial fibrosis: Functional significance and regulatory factors
33. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure: Marked upregulation of genes encoding extracellular matrix components
34. End-stage cardiac failure in humans is coupled with the induction of proliferating cell nuclear antigen and nuclear mitotic division in ventricular myocytes
35. Myocyte nuclear and possible cellular hyperplasia contribute to ventricular remodeling in the hypertrophic senescent heart in humans
36. Death by dozens of cuts
37. Cell death and the caspase cascade
38. Matrix metalloproteinases and cardiovascular disease
39. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure
40. Heart failure from the point of view of quantitative anatomy
41. Stretching cardiac myocytes stimulates proto-oncogene expression
42. Modulation of cardiac genes by mechanical stress: The oncogene signaling hypothesis
43. Mechanical activation of signaling pathways in the cardiovascular system
44. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure
45. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart
46. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension
47. Tumor necrosis factor-α provokes a hypertrophic growth response in adult cardiac myocytes
48. Plasma fas ligand, an inducer of apoptosis, and plasma soluble fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure
49. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-α
50. 1-adrenergic receptor
51. Adverse effects of chronic endogenous sympathetic drive induced by cardiac Gsa overexpression
52. αq overexpression induces cardiac contractile failure in mice
53. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: A substudy of the studies of left ventricular dysfunction (SOLVD)
54. The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy
55. Cardiomyopathy of overload: A major determinant of prognosis in congestive heart failure
56. Transcriptional regulation during cardiac growth and development
57. Functional significance of alterations in cardiac contractile protein isoforms
58. Molecular and cellular biology of heart failure
59. Changes in gene expression in the intact human heart: Downregulation of α-myosin heavy chain in hypertrophied, failing ventricular myocardium
60. Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy
61. Increased plasma concentrations of endothelin in congestive heart failure in humans
62. Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation
63. Endothelins: Myocardial actions of a new class of cytokines
64. Role of nitric oxide in the regulation of myocardial function
65. Nitric oxide and cardiac failure
66. Expression of inducible nitric oxide synthase in human heart failure
67. Signal transduction using nitric oxide and cyclic guanosine monophosphate
68. Nitric oxide inhibits the positive inotropic response to β-adrenergic stimulation in humans with left ventricular dysfunction
69. Vasodilator therapy for heart failure: The influence of impedance on left ventricular performance
70. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective randomized amlodipine survival evaluation study group
71. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST)
72. Effects of enalapril on mortality in severe congestive heart failure: Result of the cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
73. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
74. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
75. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
76. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
77. Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials
78. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomized trial
79. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF)
80. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure
81. Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy
82. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart
83. β-Adrenergic receptor blockade in chronic heart failure
84. Pheochromocytoma masquerading as a cardiomyopathy
85. Reversibility of catecholamine-induced dilated cardiomyopathy in a child with a pheochromocytoma
86. Acute reversal of pheochromocytoma-induced catecholamine cardiomyopathy
87. Possible involvement of stress-activated protein kinase signaling pathway and fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol
88. Sympathoinhibitory responses to digitalis glycosides in heart failure patients: Direct evidence from sympathetic neural recordings
89. Digoxin: A neurohormonal modulator in heart failure?
90. Digoxin reduces cardiac sympathetic activity in severe congestive heart failure
91. The effect of digoxin on mortality and morbidity in patients with heart failure
92. In vivo inhibition of elevated myocardial β-adrenergic receptor kinase activity in hybrid transgenic mice restores normal β-adrenergic signaling and function
93. New insight into the role of enhanced adrenergic receptor-effector coupling in the heart
94. Inotropes in the beta-blocker era